Key result
ARBs match ACEi for BP control and stroke prevention with fewer tolerability issues.
Why the study?
Do angiotensin receptor blockers provide similar stroke prevention and blood pressure control compared to ACE inhibitors with better tolerability?
Do angiotensin receptor blockers provide similar stroke prevention and blood pressure control compared to ACE inhibitors with better tolerability?
Angiotensin receptor blockers may offer similar stroke prevention and blood pressure control as ACE inhibitors, but with improved patient tolerability.
May support preferring ARBs in ACEI-intolerant patients; leaves open dedicated RCTs for stroke prevention.
Clinical trial results indicate that the choice of antihypertensive agent can be a determinant of stroke protection, independent of blood pressure (BP) reduction. Angiotensin-converting enzyme inhibitors (ACE-Is) are effective for BP control and stroke protection, but their use may be limited by patient tolerability. Angiotensin receptor blockers appear to provide similar BP control compared with ACE-Is and may also offer the clinician the added benefit of primary and secondary stroke prevention, with the potential for fewer tolerability issues.
No takes yet. Share an insight, caveat, or question.
Dan J. Fintel (2009) conducted a review in Stroke prevention. Angiotensin receptor blockers vs. Angiotensin-converting enzyme inhibitors was evaluated. Angiotensin receptor blockers appear to provide similar blood pressure control compared with ACE inhibitors and may offer primary and secondary stroke prevention with fewer tolerability issues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: